Inozyme Pharma Inc. (INZY)
NASDAQ: INZY
· Real-Time Price · USD
1.64
0.43 (35.54%)
At close: May 02, 2025, 3:59 PM
1.63
-0.31%
After-hours: May 02, 2025, 05:58 PM EDT
Company Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.
The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
It has a license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma Inc.
| Country | United States |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Dr. Douglas A. Treco Ph.D. |
Contact Details
Address: 321 Summer Street Boston, Massachusetts United States | |
| Website | https://www.inozyme.com |
Stock Details
| Ticker Symbol | INZY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001693011 |
| CUSIP Number | 45790W108 |
| ISIN Number | US45790W1080 |
| Employer ID | 47-5129768 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas A. Treco Ph.D. | Chief Executive Officer & Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 23, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Mar 17, 2025 | 4 | Filing |
| Mar 17, 2025 | 4 | Filing |
| Mar 17, 2025 | 4 | Filing |